Also from this source

You just read:

Cirius Therapeutics Reports Positive Data for MSDC-0602K in Interim Analysis of Phase 2b Clinical Trial in NASH Patients with Fibrosis

News provided by

Cirius Therapeutics

Oct 25, 2018, 08:00 ET